Alzheimer’s Disease
Clinical information
Definitive diagnosis of Alzheimer's disease is only possible post-mortem by means of histological examination of a brain tissue sample (detection of plaques and neurofibrillary tangles). The diagnosis of probable Alzheimer's disease can be made in the lifetime of a patient based on the clinical presence of dementia syndrome and the exclusion of possible reversible causes. Further information can be obtained by positron emission tomography (PET), which can now be used to visualise the specific neuropathological changes in living patients. Moreover, the determination of biomarkers in cerebrospinal fluid (CSF) has become established in Alzheimer's diagnostics. They are also able to indicate the disease with high reliability.
Diagnostics
The gold standard for the determination of ANA is the indirect immunofluorescence test (IIFT) with human epithelial cells (HEp-2), which is known for its high sensitivity and specificity. Positive and negative samples produce a large signal difference. In the microscopic evaluation it is possible to establish precisely how an indicator dye (generally fluorescein) is distributed in the tissue or the cells. A typical fluorescence pattern is produced for every bound autoantibody, depending on the location of the individual autoantigens.
The first international consensus on standardised nomenclature of HEp-2 cell patterns in indirect immunofluorescence (ICAP, www.anapatterns.org) defined fifteen nuclear patterns and nine cytoplasmic patterns which are relevant for the diagnosis of various autoimmune diseases.
Furthermore, the consensus recommends that autoantibodies detected in indirect immunofluorescence be confirmed by additional specific tests (e.g. ELISA, line blot). The exclusive use of these monospecific test methods is inadequate for the determination of autoantibodies against cell nuclei, as not all relevant antigens are available in a purified form as yet. Thus, the corresponding ANA can only be detected by IIFT.

The CSF of patients who will develop Alzheimer's disease show significantly decreased concentrations of Aβ1-42as early as 5 to 10 years before the onset of cognitive changes. The concentrations of total tau and pTau(181), however, increase with progressing neurodegeneration and cognitive impairment. The amyloid quotient Aβ1-42/Aβ1-40 can be useful in the differentiation of Alzheimer's disease from vascular dementia (see figure). Calculation of this quotient also reduces the distorting influences of preclinical factors on the measured concentrations.
The results obtained with CSF-based neurochemical analyses should always be assessed in the context of all available diagnostic information.
Selected Products
Method | Parameter | Substrate | Species | |
---|---|---|---|---|
ChLIA | beta-amyloid (1-40) determination in CSF | Details | ||
ELISA | beta-amyloid (1-40) determination in CSF | Details | ||
ChLIA | Control set beta-amyloid (1-40) determination in CSF | Details | ||
ChLIA | beta-amyloid (1-42) determination in CSF | Details | ||
ELISA | beta-amyloid (1-42) determination in CSF | Details | ||
ChLIA | Control set beta-amyloid (1-42) determination in CSF | Details | ||
ELISA | total tau determination in CSF | Details | ||
ELISA | pTau(181) determination in CSF | Details |